Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome.
The inhibitory role of the dopaminergic and opioidergic mechanisms in the control of LH secretion in patients with polycystic ovary syndrome (PCO) was evaluated. The administration of an opiate receptor antagonist, naloxone, of a dopamine receptor antagonist, metoclopramide, or of human synthetic beta h-endorphin, were unable to alter LH secretory activity in patients with PCO. Since identical doses of these antagonists and the opiate agonist have elicited respectively a rise and fall of LH levels in normal cycling women, these findings suggest that an underlying hypothalamic component of defect in endogenous dopamine and opioid control may be responsible for the inappropriate gonadotrophin secretion in this syndrome.
D003864:Depression, Chemical; D004723:Endorphins / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000503:physiopathology*; D007986:Luteinizing Hormone / Q000378:metabolism*; D008787:Metoclopramide / Q000494:pharmacology*; D009270:Naloxone / Q000494:pharmacology*; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D001615:beta-Endorphin
D004723:Endorphins; D009270:Naloxone; D001615:beta-Endorphin; D007986:Luteinizing Hormone; D008787:Metoclopramide